

Lay out of the cohort information for the CITB Biobank

Cohort Name

Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling - OptimAT (NCT03477331)

Principal Investigator

Prof Jean-Luc Reny

e-mail

Jean-Luc.Reny@hcuge.ch

Address

Hôpitaux Universitaires de Genève
Rue Gabrielle-Perret-Gentil 4
1205 Genève
Tel. 022 30 56 500

Institution

Hôpitaux Universitaires de Genève

Cohort description

Hospitalized patients at any of the Geneva University Hospitals - Treated with DOAC (dabigatran, rivaroxaban, apixaban) or/and P2Y12 (clopidogrel, ticagrelor et prasugel) and included in the OptimAT study. The goal of the OptimAT study is to validate populationnal and physiologically-based pharmacokinetic models to predict antithrombotics' concentrations in hospitalized patients. A biobank (serum, plasma, DNA, mRNA) has been created in order to allow deriving or validating relevant biomarkers for the biological and clinical outcomes of interest such as cytochromes genotyping. This biobank will allow further research in various areas including the identification of novel prognostic biomarkers, pathways involved in drug response and pharmacogenetic studies.

Type

Prospective

Size

400-600 patients

Gender

Female and male

Age

18 yo and older

Storage temperature

-80°C

Material types

Serum, plasma, DNA, mRNA

Available data

Available diagnosis

Data will be stored on a secure server with restricted access HUG investigators and collaborators of the study with task delegation.

Sample access rules

Two compartments are provided for the storage of biological samples biobank in a freezer at -80 ° C of Geneva Platelet Group located in the premises of the serum bank Opera HUG. Access to the premises is secured with badge.

Ethical committee:

CCER Genève n°2017-00225

Commercial collaboration

No

Non-for profit collaboration

Not yet but will be considered in the future.